Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | JUN | P05412 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | MAPK6 | Q16659 | 3/20 | 0.39 |
| ▸ | MAPKAPK3 | Q16644 | 2/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.39 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24076877 | 0.88 | MAPT (0.39) | MAPTPARP1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL24076879 | 0.84 | DAO (0.38) | MAPTPRMT5WDR77NFKB1NFKB2 | |
| SCHEMBL26732593 | 0.78 | MAPT (0.45) | MAPTPARP1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL30451535 | 0.78 | MAPT (0.45) | MAPTPARP1SMN1; SMN2PRMT5WDR77 | |
| SCHEMBL25279396 | 0.78 | TRPA1 (0.55) | MAPTHSD17B10GSK3BMAP2K4MAPK1 | |
| SCHEMBL30481233 | 0.78 | TRPA1 (0.55) | MAPTHSD17B10GSK3BMAP2K4MAPK1 | |
| SCHEMBL30481232 | 0.78 | MAP2K4 (0.56) | KDM4EGSK3BMAP2K4MAPK1MAPK6 | |
| SCHEMBL25241733 | 0.78 | MAP2K4 (0.56) | KDM4EGSK3BMAP2K4MAPK1MAPK6 | |
| SCHEMBL24076903 | 0.78 | PRMT5 (0.48) | PRMT5WDR77AURKBGSK3B | |
| SCHEMBL24077199 | 0.77 | HTT (0.47) | SMN1; SMN2PRMT5WDR77KDM4EGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4567028-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2025-06-11 | — | — | EP | disclosed |
| EP-4330235-B1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-12 | — | — | EP | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-18 | — | — | US | disclosed |
| EP-4330235-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN Pharmaceutica NV (BE) | 2024-03-06 | — | — | EP | disclosed |
| CN-117279899-A | Phthalazinone derivatives as NLRP3 inflammatory corpuscle inhibitors | 詹森药业有限公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| EP-4157823-A1 | COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-04-05 | — | — | EP | disclosed |
| CN-115667225-A | Compound (I) | 詹森药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2022229315-A1 | PHTHALAZINONE DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-11-03 | — | — | WO | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | MAPT 1004/4885PARP1 403/4885SMN1; SMN2 4739/4885 |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | MAPT 3736/4885PARP1 1511/4885SMN1; SMN2 4102/4885 |
| US-20240239757-A1 | PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS | NLRP3, NLRP1, PYCARD | MAPT 162/4885PARP1 499/4885SMN1; SMN2 4494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.